First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies
Naoto Morikawa(Tohoku University), Akihiko Gemma(Nippon Medical School), Kunihiko Kobayashi(Saitama International Medical Center), Akira Inoue(Tohoku University Hospital), Shoji Okinaga(Tohoku University), Satoshi Oizumi(Hokkaido University), Shunichi Sugawara(Sendai Kousei Hospital), Yuji Minegishi, Toshihiro Nukiwa(Tohoku University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Masao Harada(Shikoku Cancer Center), Koichi Hagiwara(Jichi Medical University)
Cited by 33
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953